BPTSY (Biophytis) Cash Flow from Investing: $ Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BPTSY Biophytis SA BPTSY
19 GF Score
Price $0.25
! 4 Warning Signs
View Full Analysis

What is Biophytis Cash Flow from Investing?

Biophytis BPTSY 19 Cash Flow from Investing is $ Mil as of Dec. 2025. GuruFocus rates BPTSY with a GF Score™ of 19/100. The stock has 4 warning signs investors should review.

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the six months ended in Dec. 2025, Biophytis spent $0.00 Mil on purchasing property, plant, equipment. It gained $ Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $ Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Biophytis gained $ Mil on investment activities in financial market and operating subsidiaries for the six months ended in Dec. 2025.


Biophytis  (OTCPK:BPTSY) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Biophytis's purchase of property, plant, equipment for the six months ended in Dec. 2025 was $ Mil. It means Biophytis spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Biophytis's sale of property, plant, equipment for the six months ended in Dec. 2025 was $ Mil. It means Biophytis gained $ Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Biophytis's purchase of business for the six months ended in Dec. 2025 was $ Mil. It means Biophytis spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Biophytis's sale of business for the six months ended in Dec. 2025 was $0.00 Mil. It means Biophytis gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Biophytis's purchase of investment for the six months ended in Dec. 2025 was $ Mil. It means Biophytis spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Biophytis's sale of investment for the six months ended in Dec. 2025 was $ Mil. It means Biophytis gained $ Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Biophytis's net Intangibles purchase and sale for the six months ended in Dec. 2025 was $ Mil. It means Biophytis paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Biophytis's cash from discontinued investing activities for the six months ended in Dec. 2025 was Mil. It means Biophytis paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Biophytis's cash from other investing activities for the six months ended in Dec. 2025 was $ Mil. It means Biophytis paid $0.00 Mil for other investing activities.


Biophytis Cash Flow from Investing Related Terms


Biophytis Cash Flow from Investing Historical Data

* Premium members only.

The historical data trend for Biophytis's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biophytis Cash Flow from Investing Chart

Biophytis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.37 -0.02 0.40 0.01 -

Biophytis Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.24 -0.01 0.02 0.00 -
BPTSY
19GF Score
Biophytis SA BPTSY
Cash Flow from Investing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biophytis Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Biophytis's Cash Flow from Investing for the fiscal year that ended in Dec. 2025 is calculated as:

Biophytis's Cash Flow from Investing for the quarter that ended in Dec. 2025 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Investing of $ Mil mean?
Biophytis (BPTSY) has a Cash Flow from Investing of $ Mil as of Dec. 2025. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for Biophytis and its competitors.
Is Biophytis' Cash Flow from Investing too high?
Biophytis' current Cash Flow from Investing is $ Mil. Overall, Biophytis has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Biophytis' Cash Flow from Investing compare to VRTX and REGN?
Biophytis' Cash Flow from Investing of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Investing for a Biotechnology company?
A good Cash Flow from Investing depends on the Biotechnology industry context. However, Cash Flow from Investing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Investing mean?
A high Cash Flow from Investing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for Biophytis and its competitors. Biophytis's current Cash Flow from Investing is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biophytis stock overvalued right now?
Biophytis (BPTSY) has a current Cash Flow from Investing of $ Mil. The current Cash Flow from Investing is $ Mil. Biophytis' overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Investing calculated?
Cash Flow from Investing is calculated from a company's financial statements. For Biophytis (BPTSY), the current Cash Flow from Investing is $ Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biophytis Business Description

Address BC 9, Batiment A 4eme etage, 4 Place Jussieu, Sorbonne University, Paris, FRA, 75005
Biophytis SA is a French clinical-stage biotechnology company that develops drug candidates for age-related and respiratory diseases. Its lead candidate, BIO101 (20-hydroxyecdysone), is an orally administered small molecule that acts on the renin-angiotensin system and is being studied for neuromuscular and respiratory indications, including sarcopenia, Duchenne muscular dystrophy, and respiratory failure associated with conditions such as COVID-19. The company also has earlier-stage programs, including BIO102 and BIO103, targeting degenerative processes linked to aging. Biophytis operates primarily in France, with research and development activities conducted in-house and through partnerships, and it has pursued clinical trials in Europe and other regions. As a clinical-stage company, it has no marketed products and generates no product revenue, relying on equity financing, public grants, and partnership funding to advance its pipeline.
19GF Score

Get the complete analysis for BPTSY

Cash Flow from Investing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price